Nigeria's monkeypox outbreak represents opportunity for Danish company still looking to overcome cancer vaccine setback.
Bavarian Nordic AS has gained US Food and Drug Administration approval for Jynneos, making it the first approved non-replicating smallpox vaccine in the US and the only approved monkeypox vaccine anywhere in the world.
Jynneos (MVA-BN, liquid-frozen) is a live, non-replicating vaccine, which means it can be administered to people who are at high risk of adverse reaction to traditional,
As CEO Anderson backs high prices for innovative drugs in Europe
Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).
As CEO Anderson backs high prices for innovative drugs in Europe
Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.
The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.
